Skip to main content

Table 1 Characteristics of all amplicons used in genotyping assay. Detailed results for individual SNPs within all non-immune loci included in the final assay is provided in the Additional file 1: Tables S1 and S2

From: Development of a SNP-based assay for measuring genetic diversity in the Tasmanian devil insurance population

Amplicon

Target variation

Chra

Length (bp)

No. of SNPs

No. of SNPs not in HWE

No. of haplotypes

AGA

Neutral

6

9352

34

2 (6 %)

2

CCLD5/6b

Chemokine

4

8209

25

22 (88 %)

18

CX3Cb

Chemokine

1

9425

3

1 (33 %)

6

DIG12b

NK receptor

3

6351

15

0 (0 %)

3

DIG24b

NK receptor

3

6809

1

1 (100 %)

2

DRD5

Dopamine receptor

6

7885

1

0 (0 %)

2

ERN2

Pro-apoptotic

2

10,165

17

17 (100 %)

2

FOXA2

Neutral

1

10,122

39

4 (10 %)

29

IL17Bb

Interleukin

1

5717

20

1 (5 %)

2

IL22F1b

Interleukin

1

6531

3

2 (67 %)

3

KIT

Neutral

2

8356

2

1 (50 %)

3

NF2

Neutral

2

9312

41

1 (2 %)

3

PLEKHM3

Neutral

3

10,034

16

2 (13 %)

5

RAB27A

Neutral

1

10,077

2

0 (0 %)

3

TGFB1b

Cytokine

3

2649

2

0 (0 %)

3

TLR3b

Toll-like receptor

6

7663

32

4 (13 %)

6

UNC13B

Neutral

2

9687

14

0 (0 %)

3

Total

  

138,344

267

58

95

  1. Nb. Amplicons are named according to nearest annotated gene: amplicons are not necessarily targeting the gene they are named for
  2. aChromosome as indicated by Tasmanian devil reference genome v7.1 [32] however recent work has identified that chromosomes 1 and 2 were mis-identified [50]
  3. bIndicates immune-targeted amplicon [40]